{ "labelLang" : "hun", "responseDate" : "2024-03-29 10:38", "content" : { "otype" : "BookChapter", "mtid" : 30812865, "status" : "APPROVED", "published" : true, "comment" : "Export Date: 23 September 2019 \n Correspondence Address: Dhawan, D.; PanGenomics International Pvt. Ltd.India\nExport Date: 22 June 2021 \n Correspondence Address: Dhawan, D.; PanGenomics International Pvt. Ltd.India", "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2023-09-18T10:06:32.549+0000", "lastModified" : "2020-02-28T09:28:50.247+0000", "created" : "2019-09-23T10:51:20.120+0000", "creator" : { "otype" : "Admin", "mtid" : 10028537, "link" : "/api/admin/10028537", "label" : "Baczkó Gabriella (SZTE ÁOK admin5 Reuma és Farmakológia)", "familyName" : "Baczkó", "givenName" : "Gabriella", "published" : true, "oldId" : 10028537, "snippet" : true }, "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 25, "link" : "/api/publicationtype/25", "label" : "Könyvrészlet", "code" : 25, "otypeName" : "BookChapter", "listPosition" : 2, "published" : true, "oldId" : 25, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000398, "link" : "/api/subtype/10000398", "label" : "Könyvfejezet (Könyvrészlet)", "name" : "Könyvfejezet", "nameEng" : "Chapter", "docType" : { "otype" : "PublicationType", "mtid" : 25, "link" : "/api/publicationtype/25", "label" : "Könyvrészlet", "code" : 25, "otypeName" : "BookChapter", "listPosition" : 2, "published" : true, "oldId" : 25, "snippet" : true }, "listPosition" : 220, "published" : true, "oldId" : 10000398, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Dhawan, D.", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 88034566, "link" : "/api/authorship/88034566", "label" : "Dhawan, D. ✉", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "corresponding" : true, "familyName" : "Dhawan", "givenName" : "D.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "Biotechnology for biomarkers: Towards prediction, screening, diagnosis, prognosis, and therapy", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 15916295, "link" : "/api/publicationidentifier/15916295", "label" : "DOI: 10.1016/B978-0-12-804659-3.00023-3", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1016/B978-0-12-804659-3.00023-3", "realUrl" : "https://doi.org/10.1016/B978-0-12-804659-3.00023-3", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 18944911, "link" : "/api/publicationidentifier/18944911", "label" : "WoS: 000472755200023", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000472755200023", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/000472755200023", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 15916294, "link" : "/api/publicationidentifier/15916294", "label" : "Scopus: 85054379185", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85054379185", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85054379185", "published" : false, "snippet" : true } ], "firstPage" : "533", "lastPage" : "557", "firstPageOrInternalIdForSort" : "533", "pageLength" : 25, "publishedYear" : 2017, "digital" : null, "printed" : null, "sourceYear" : 2019, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : null, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2023-09-18", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 1, "citedCount" : 1, "referenceList" : "Akdogan, M., Sasmaz, N., Kayhan, B., Biyikoglu, I., Disibeyaz, S., Sahin, B., Extraordinarily elevated CA19-9 in benign conditions: a case report and review of literature (2001) Tumori, 87, pp. 337-339 ;\n Allison, A.C., Protection afforded by sickle-cell trait against subtertian+ malarial infection (1954) BMJ, 1, pp. 290-294 ;\n Antman, E., Decision making with cardiac troponin tests (2002) N. Engl. J. Med, 346, pp. 2079-2082 ;\n (2007), Approval Letter from Richard Padzur, M.D., CDER, FDA, to SmithKline Beecham Corp. (March 13) ;\n Balog, A., Klausz, G., Gál, J., Molnár, T., Nagy, F., Ocsovszky, I., Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis (2004) Pathobiology, 71, pp. 274-280 ;\n Bast, R.C., Badgwell, D., Lu, Z., Marquez, R., Rosen, D., Liu, J., New tumor markers: CA 125 and beyond (2005) Int. J. Gynecol. Cancer, 15, pp. 274-281 ;\n Bowes, J.D., Potter, C., Gibbons, L.J., Hyrich, K., Plant, D., Morgan, A.W., Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients (2009) Pharmacogenet. Genomics, 19, pp. 319-323 ;\n Burstein, H.J., The distinctive nature of HER2-positive breast cancer (2005) N. Engl. J. Med, 353 (16), pp. 1652-1654 ;\n Combe, B., Dougados, M., Gouille, P., Cantagrel, A., Eliaou, J.F., Sibilia, J., Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study (2001) Arthritis Rheum, 44, pp. 1736-1743 ;\n Coulthard, L.R., Taylor, J.C., Eyre, S., Robinson, J.I., Wilson, A.G., Genetic variants within the MAP kinase signalling network and antiTNF treatment response in rheumatoid arthritis patients (2011) Ann. Rheum. Dis, 70, pp. 98-103 ;\n Criswell, L.A., Lum, R.F., Turner, K.N., Woehl, B., Zhu, Y., Wang, J., The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept (2004) Arthritis Rheum, 50, pp. 2750-2756 ;\n Dean, M., Carrington, M., Winkler, C., Huttley, G.A., Smith, M.W., Allikmets, R., Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene (1996) Science, 273, pp. 1856-1862 ;\n de Roda Husman, A.M., Koot, M., Cornelissen, M., Keet, I.P., Brouwer, M., Broersen, S.M., Association between CCR5 genotype and the clinical course of HIV-1 infection (1997) Ann. Intern. Med, 127, pp. 882-890 ;\n Dollery, C.M., McEwan, J.R., Henney, A.M., Matrix metalloproteinases and cardiovascular disease (1995) Circ. Res, 77, pp. 863-868 ;\n Epstein, R.S., Toyer, T.P., Aubert, R.E., O'Kane, D.J., Xia, F., Verbrugge, R.R., Warfarin genotyping reduces hospitalisation rates: Results from the MM-WES (Medco-Mayo Effectiveness Study) (2010) J. Am. Coll. Cardiol, 55 (25), pp. 2804-2812 ;\n (2009), Erbitux Prescribing Information, 1.2. Approval letter for P030044 from Steven I. Gutman, M.D., M.B.A., CDRH, FDA, to Ronald F. Lagerquist, DakoCytomation California, Inc. (Feb. 12, 2004) ;\n (2009), Erbitux Prescribing Information, 5.7 ;\n (2004) Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products, , http://www.fda.gov/oc/initiatives/criticalpath, US Department of Health and Human Services ;\n (2005) Guidance for Industry: Pharmacogenomic Data Submissions, , http://www.fda.gov/cber/gdlns/pharmdtasub.pdf, US Department of Health and Human Services ;\n (2005) 510(k) Substantial Equivalence Determination Decision Summary for K042884, DakoCytomation ER/PR pharmDx™ Kit, section H ;\n (2006), p. 18. , FDA Critical Path Opportunities Report ;\n Frueh, F.W., Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use (2008) Pharmacotherapy, 28, pp. 992-997. , Camptosar Prescribing Information, Dosage and Administration & Warnings sections (July 2008). Lower Drug Dose Spells Trouble for Pharmacogenetic Test, The Gray Sheet (June 25, 2007), at 10 ;\n Frey, N., Muller-Bardorff, M., Katus, H.A., Myocardial damage: the role of troponin T (1998) Myocardial Damage. Early Detection by Novel Biochemical Markers, pp. 27-40. , Kluwer Academic Publishers, Boston, MA, J.C. Kaski, D.W. Holt (Eds.) ;\n Genebat, M., Ruiz-Mateos, E., Leon, J.A., Gonzalez-Serna, A., Pulido, I., Rivas, I., Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients (2009) J. Antimicrob. Chemother, 64, pp. 845-849 ;\n Greener, M., (2006) SNPs: Driving Variability and Tailoring Treatments, , http://www.dddmag.com/ShowPR_Print.aspx?PUBCODE=016&ACCT=1600000100&ISSUE=0407&RELTYPE=PR&ORIGRELTYPE=GPF&PRODCODE=00000000&PRODLETT=Y&CALLFROM=RELPGM, Drug Discovery and Development ;\n Gregersen, P.K., Silver, J., Winchester, R.J., The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis (1987) Arthritis Rheum, 30, pp. 1205-1213 ;\n Hafler, J.P., Maier, L.M., Cooper, J.D., Plagnol, V., Hinks, A., Simmonds, M.J., CD226, Gly307Ser association with multiple autoimmune diseases (2009) Genes Immun, 10, pp. 5-10 ;\n (2009), Herceptin Prescribing Information, 5.5 ;\n Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir (2001) Clin. Ther, 23, pp. 1603-1614 ;\n Hill, A.V., Aspects of genetic susceptibility to human infectious diseases (2006) Annu. Rev. Genet, 40, pp. 469-486 ;\n Houlka, B.S., Overview of biological markers (1990) Biological Markers in Epidemiology, pp. 3-15. , http://www.accessdata.fda.gov/cdrh_docs/reviews/K042884.pdf, Oxford University Press, New York ;\n (2008), Id: Approval Letter for P050040 from Maria M. Chau, Ph.D., FDA, to Kelli L. Tanzella, Ph.D., Invitrogen Corp. (July 1) ;\n (2008) Imuran Prescribing Information, Clinical Pharmacology Section ;\n Lindsay, M.M., Maxwell, P., Dunn, F.G., TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension (2002) Hypertension, 40, pp. 136-141 ;\n Liu, R., Paxton, W.A., Choe, S., Ceradini, D., Martin, S.R., Horuk, R., Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection (1996) Cell, 86, pp. 367-377 ;\n Ludwig, J.A., Weinstein, J.N., Biomarkers in cancer staging, prognosis and treatment selection (2005) Nat. Rev. Cancer, 5 (11), pp. 845-856 ;\n Luscher, M.S., Thygesen, K., Ravkilde, J., Heickendorff, L., Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease (1997) Circulation, 96, pp. 2578-2585 ;\n Mallal, S., Phillips, E., Carosi, G., Molina, J.M., Workman, C., Tomazic, J., HLA-B*5701 screening for hypersensitivity to abacavir (2008) N. Engl. J. Med, 358, pp. 568-579 ;\n Marotte, H., Pallot-Prades, B., Grange, L., Tebib, J., Gaudin, P., Alexandre, C., The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population (2006) Ann. Rheum. Dis, 65, pp. 342-347 ;\n Martin, K., Hammond, M., Henderson, S., (2006) The eClinical equation: Part 2-bridging connections for innovation, , http://www-935.ibm.com/services/us/index.wss/ibvstudy/gbs/a1025940?cntxt=a1000060, IBM Institute for Business Value ;\n Martin, M.P., Dean, M., Smith, M.W., Winkler, C., Gerrard, B., Michael, N.L., Genetic acceleration of AIDS progression by a promoter variant of CCR5 (1998) Science, 282, pp. 1907-1911 ;\n Martinez, A., Salido, M., Bonilla, G., Pascual-Salcedo, D., Femandez-Arquero, M., de Miguel, S., Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients (2004) Arthritis Rheum, 50, pp. 1077-1082 ;\n Mills, G., (2007), January. FDA Update. IBM (Imaging) Biomarker Summit III ;\n Morel, J., Combe, B., How to predict prognosis in early rheumatoid arthritis (2005) Best. Prac. Res. Clin. Rheumatol, 19, pp. 137-146 ;\n Mugnier, B., Balandraud, N., Darque, A., Roudier, C., Roudier, J., Reviron, D., Polymorphism at position-308 of the tumour necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis (2003) Arthritis Rheum, 48, pp. 1849-1852 ;\n (2005) Nat'l Urea Cycle Disorders Foundation, , http://www.nucdf.org/ucd.htm, What is a Urea Cycle Disorder? ;\n O'Connell, D., Roblin, D., Translational research in the pharmaceutical industry: from bench to bedside (2006) Drug Discov. Today, 11 (17-18), pp. 833-838 ;\n O'Dwyer, P.J., Catalano, R.B., UGT1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy (2006) J. Clin. Oncol, 24 (28), pp. 4534-4538 ;\n Padyukov, L., Lampa, J., Heimbürger, M., Ernestam, S., Cederholm, T., Lundkvist, I., Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis (2003) Ann. Rheum. Dis, 62, pp. 526-529 ;\n (2004) Background document on the UGT1A1 polymorphisms and irinotecan toxicity, , http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4079B1_07_Pfizer-UGT1A1.pdf, ACPS November 2004 Advisory Committee Meeting, published on the FDA ;\n Potter, C., Cordell, H.J., Barton, A., Daly, A.K., Hyrich, K.L., Mann, D.A., Association between anti-tumor necrosis factor treatment response and genetic variants within the TLR and NF[kappa]B signalling pathways (2010) Ann. Rheum. Dis, 69, pp. 1315-1320 ;\n (1998), Press Release, HHS, New Monoclonal Antibody Approved for Advanced Breast Cancer, supra note 100 ;\n Center for Biologics Evaluation and Research, FDA, Clinical Review Briefing Document: sBLA STN: 103792/5008/0, Trastuzumab, at 4 (November 5, 2001) ;\n see also Herceptin Prescribing Information, Clinical Studies section (Immunohistochemical Detection)1 (September) ;\n Raychaudhuri, S., Thomson, B.P., Remmers, E.F., Eyre, S., Hinks, A., Guiducci, C., Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk (2009) Nat. Genet, 41, pp. 1313-1318 ;\n Relling, M., Dervieux, T., Pharmacogenetics and cancer therapy (2001) Nat. Rev. Cancer, 1, pp. 99-108 ;\n (2008) Rifater Prescribing Information, , Clinical Pharmacology Section (April) ;\n Salkowitz, J.R., Bruse, S.E., Meyerson, H., Valdez, H., Mosier, D.E., Harding, C.V., CCR5 promoter polymorphisms determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro (2003) Clin. Immunol, 108, pp. 234-240 ;\n Samson, M., Libert, F., Doranz, B.J., Rucker, J., Liesnard, C., Farber, C.M., Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene (1996) Nature, 382, pp. 722-725 ;\n Scirica, B.M., Morrow, D.A., Cannon, C.P., de Lemos, J.A., Murphy, S., Sabatine, M.S., Clinical application of C-reactive protein across the spectrum of acute coronary syndromes (2007) Clin. Chem, 53, pp. 1800-1807 ;\n Stahl, E.A., Raychaudhuri, S., Remmers, E.F., Xie, G., Eyre, S., Thomson, B.P., Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci (2010) Nat. Genet, 42, pp. 508-514 ;\n (2005) Talk Paper, FDA, FDA Approves Drug for Advanced Colorectal Cancer, , T96-42 (June 17, 1996) ;\n 510(k) Summary for Invader UGT1A1 Molecular Assay 11 (Aug. 18) ;\n Tan, R.J., Gibbons, L.J., Potter, C., Hyrich, K.L., Morgan, A.W., Wilson, A.G., Investigation of rheumatoid arthritis susceptibility gene identifies association of AFF3 and CD226 variants with response to anti-tumor necrosis factor alpha therapy (2010) Ann. Rheum. Dis, 69, pp. 1029-1035 ;\n Thygesen, K., Alpert, J.S., White, H.D., Jaffe, A.S., Apple, F.S., Galvani, M., Joint ESC/ACCf/AHA/WHF task force for the redefinition of myocardial infarction, universal definition of myocardial infarction (2007) Circulation, 116, pp. 2634-2653 ;\n Trusheim, M.R., Berndt, E.R., Douglas, F.L., Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers (2007) Nat. Rev. Drug Discov, 6, pp. 287-293 ;\n (2007) Tykerb Prescribing Information, , March 14 ;\n van Haaften-Day, C., Shen, Y., Xu, F., Yu, Y., Berchuck, A., Havrilesky, L.J., OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal (2001) Cancer, 92, pp. 2837-2844 ;\n Wong, S.S., Strategic utilization of cardiac markers for the diagnosis of acute myocardial infarction (1996) Ann. Clin. Lab. Sci, 26, pp. 301-312 ;\n Biomarkers: Physiological and Laboratory Markers of Drug Effect (2007) National Institutes of Health Clinical Center, , http://clinicalcenter.nih.gov/researchers/training/principles/ppt/woodcock_2006-2007.ppt, Woodcock J ;\n Xeloda Prescribing Information, Contraindications, Precautions, & Clinical Pharmacology Sections, , November 2009 ;\n see also Carac (fluorouracil cream) Prescribing Information, Contraindications and Warnings sections (November 2006) noting this drug also should not be given to patients with DPD deficiency due to risk of serious toxicity ;\n Yurkovetsky, Z., Ta'asan, S., Skates, S., Rand, A., Lomakin, A., Linkov, F., Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin (2007) Gynecol. Oncol, 107, pp. 58-65 ;\n Yurkovetsky, Z., Skates, S., Lomakin, A., Nolen, B., Pulsipher, T., Modugno, F., Development of a multimarker assay for early detection of ovarian cancer (2010) J. Clin. Oncol, 28, pp. 2159-2166 ;\n Yurkovetsky, Z.R., Linkov, F.Y., Malehorn, E.D., Lokshin, A.E., Multiple biomarker panels for early detection of ovarian cancer (2006) Future Oncol, 2, pp. 733-74", "hasCitationDuplums" : false, "directInstitutesForSort" : "", "ownerAuthorCount" : 7, "ownerInstituteCount" : 14, "directInstituteCount" : 0, "authorCount" : 1, "contributorCount" : 0, "book" : { "otype" : "Book", "mtid" : 30354335, "link" : "/api/publication/30354335", "label" : "Barh D. Omics Technologies and Bio-engineering: Towards Improving Quality of Life. (2018) ISBN:9780128047491; 9780128046593", "core" : false, "citation" : false, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 23, "link" : "/api/publicationtype/23", "label" : "Könyv", "code" : 23, "otypeName" : "Book", "listPosition" : 3, "published" : true, "oldId" : 23, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000201, "link" : "/api/subtype/10000201", "label" : "Szakkönyv (Könyv)", "name" : "Szakkönyv", "nameEng" : "Monograph", "docType" : { "otype" : "PublicationType", "mtid" : 23, "link" : "/api/publicationtype/23", "label" : "Könyv", "code" : 23, "otypeName" : "Book", "listPosition" : 3, "published" : true, "oldId" : 23, "snippet" : true }, "listPosition" : 337, "published" : true, "oldId" : 10000201, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "title" : "Omics Technologies and Bio-engineering: Towards Improving Quality of Life", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 20587776, "link" : "/api/publicationidentifier/20587776", "label" : "DOI: 10.1016/C2015-0-01634-3", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "idValue" : "10.1016/C2015-0-01634-3", "realUrl" : "https://doi.org/10.1016/C2015-0-01634-3", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 15067562, "link" : "/api/publicationidentifier/15067562", "label" : "ISBN: 9780128047491", "source" : { "otype" : "PlainSource", "mtid" : 122, "link" : "/api/publicationsource/122", "label" : "ISBN", "type" : { "otype" : "PublicationSourceType", "mtid" : 10002, "link" : "/api/publicationsourcetype/10002", "label" : "Egyéb", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "ISBN", "nameEng" : "ISBN", "linkPattern" : "https://www.worldcat.org/search?q=isbn%3A@@@", "publiclyVisible" : true, "published" : true, "oldId" : 122, "snippet" : true }, "idValue" : "9780128047491", "realUrl" : "https://www.worldcat.org/search?q=isbn%3A9780128047491", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 15067563, "link" : "/api/publicationidentifier/15067563", "label" : "ISBN: 9780128046593", "source" : { "otype" : "PlainSource", "mtid" : 122, "link" : "/api/publicationsource/122", "label" : "ISBN", "type" : { "otype" : "PublicationSourceType", "mtid" : 10002, "link" : "/api/publicationsourcetype/10002", "label" : "Egyéb", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "ISBN", "nameEng" : "ISBN", "linkPattern" : "https://www.worldcat.org/search?q=isbn%3A@@@", "publiclyVisible" : true, "published" : true, "oldId" : 122, "snippet" : true }, "idValue" : "9780128046593", "realUrl" : "https://www.worldcat.org/search?q=isbn%3A9780128046593", "published" : false, "snippet" : true } ], "publishedAt" : [ { "otype" : "City", "mtid" : 10483, "link" : "/api/city/10483", "label" : "London, Egyesült Királyság / Anglia", "partOf" : { "otype" : "Country", "mtid" : 10175, "link" : "/api/country/10175", "label" : "Egyesült Királyság / Anglia", "published" : true, "oldId" : 2151760, "snippet" : true }, "published" : true, "oldId" : 1022850, "snippet" : true } ], "publishedYear" : 2018, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "published" : true, "snippet" : true }, "hasQualityFactor" : false, "link" : "/api/publication/30812865", "label" : "Dhawan D.. Biotechnology for biomarkers: Towards prediction, screening, diagnosis, prognosis, and therapy. (2017) Megjelent: Omics Technologies and Bio-engineering: Towards Improving Quality of Life pp. 533-557", "template" : "